NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.
Ann Surg Oncol
; 30(11): 6558-6566, 2023 Oct.
Article
in En
| MEDLINE
| ID: mdl-37368098
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Bile Duct Neoplasms
/
Cholangiocarcinoma
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
/
Middle aged
Language:
En
Journal:
Ann Surg Oncol
Journal subject:
NEOPLASIAS
Year:
2023
Type:
Article
Affiliation country:
United States